Human Microbiome Therapeutics Market By Product Type (Prebiotics, Probiotics, Symbiotics, Xenobiotics), By Application (Obesity, Diabetes, Autoimmune Disorders, Cancer, Gastrointestinal Disorders, Central Nervous System Disorders, Skin Care and Oral Care, Others), and Geography  

Human Microbiome Therapeutics Market size was valued at USD 456.2 million in 2022 and is poised to grow at a significant CAGR of 22.3% from 2023-29. The microbiome is the collective genomes of the microbes consisting of bacteria, bacteriophage, fungi, protozoa, and viruses that live inside the human body. The human microbiota is made of around 10-100 trillion symbiotic microbial cells harbored by each person, primarily in the human gut. The presence of a healthy microbiome is necessary to perform specific sets of biomolecular functions in each biochemical environment across the body, especially in stomach flora and intestinal flora. Gut microbes respond quickly to a change in diet, which means the composition of the microbiome can be changed by changing eating habits. The increasing applications of microbiome-based products in human health and technological advancements in the microbiome industry are driving the global human microbiome market growth. Also, the increasing number of digestive disorders is fueling the growth of the overall human microbiome market. For example, according to WHO, digestive disorders accounted for 375,170 deaths, 215,168 deaths in men, and 160,002 deaths in women, a crude rate of 37.2 deaths per 100,000 population (43.3 deaths/100,000 in men and 31.3 deaths/100,000 in women) worldwide in 2019. Hence, the increasing focus on human microbiome therapeutics development is the major driver in the global market. Moreover, the launches of new products in this market and collaboration between public-private organizations are influencing the global human microbiome market trend due to various high growth opportunities. The global key players are continuously driving market growth through mergers, acquisitions, and innovations. However, stringent government regulations in the industry and the lack of awareness about human microbiome products may hamper the global human microbiome market growth. Geographically, North America held the major market share in the global human microbiome market and is expected to dominate the global market in the forecasted years.

Human Microbiome Therapeutics Market Key Developments:

• In Sept 2022, Enterome's OncoMimics-based immunotherapy EO2401 was distinguished with the 'Best Clinical Research Award' at EANO Meeting 2022.
• In April 2022, Vedanta Biosciences announced the publication in the journal Cell Host & Microbe of the results from a Phase 1a/1b study evaluating the safety, tolerability, and colonization dynamics of VE303 in healthy adults.